DYNAMICS OF HEART RATE VARIABILITY AND VENTRICULAR ECTOPIC ACTIVITY IN IVABRADINE-TREATED PATIENTS WITH CHRONIC HEART FAILURE
Abstract
Aim. In patients with chronic heart failure (CHF) of ischemic aetiology, to assess the dynamics of heart rate variability (HRV) and ventricular ectopic activity during the complex, ivabradine-including therapy. Material and methods. In total, 90 patients with CHF and stable angina pectoris were examined. All participants were randomised into three equally sized groups: Group 1, receiving perindopril and ivabradine, as a part of the complex treatment; Group 2, receiving perindopril, bisoprolol, and ivabradine; and Group 3, receiving perindopril and bisoprolol. The therapy duration was 6 months. At baseline and in the end of the treatment phase, the following parameters were assessed: HRV measures (mean 24-hour hear rate (HR), SDNN, triangular index (HRVti), and mean weighted variation of rhythmogram (MWVR)); mean 24-hour QT, QTc, QTc dispersion (QTcd), and ventricular extrasystolia (VE). Results. The treatment was associated with a significantly greater reduction of mean 24-hour HR in Groups 1 and 2 vs. Group 3 (p<0,001). In Group 3, the SDNN increase was significantly lower than in Groups 1 and 2 (p><0,001), where SDNN values were similar (p=0,091). Group 3 also demonstrated a significantly ><0,001). In Group 3, the SDNN increase was significantly lower than in Groups 1 and 2 (p<0,001), where SDNN values were similar (p=0,091). Group 3 also demonstrated a significantly ><0,001), where SDNN values were similar (p=0,091). Group 3 also demonstrated a significantly lower increase in MWVR, compared to Groups 1 and 2 (p<0,001). This parameter was similar in Groups 1 and 2 (p=0,065). The increase in HRVti was more pronounced in Group 2 than in Groups 1 and 3 (p><0,001). The reduction in the total 24-hour VE number was significantly more pronounced in Group 2 than in Groups 1 and 3 (p><0,001). The dynamics of 24-hour QTc and QTcd was similar across three groups.><0,001). This parameter was similar in Groups 1 and 2 (p=0,065). The increase in HRVti was more pronounced in Group 2 than in Groups 1 and 3 (p<0,001). The reduction in the total 24-hour VE number was significantly more pronounced in Group 2 than in Groups 1 and 3 (p<0,001). The dynamics of 24-hour QTc and QTcd was similar across three groups. Conclusion. Including ivabradine in the complex therapy of patients with CHF and stable angina pectoris was associated with improved HRV, no marked QTc or QTcd changes, and a moderate preventive effect on VE.
About the Authors
M. V. SurovtsevaRussian Federation
N. A. Koziolova
Russian Federation
A. I. Chernyavina
Russian Federation
References
1. Fomin I. V. Epidemiology of chronic heart failure in Russian Federation. In. Belenkov Yu. N., Ageev F. T., Arutjunov G. P., Vasyuk Yu. A. Chronic heart failure. Moscow: Geotar-Media; 2010. pp. 7–77. Russian (Фомин И. В. Эпидемиология хронической сердечной недостаточности в Российской Федерации. В кн.: Хроническая сердечная недостаточность (Беленков Б. Н., Агеев Ф. Т., Арутюнов Г. П., Васюк Ю. А.) М.: ГЕОТАР-Медиа 2010,7–77.
2. Huikuri H. V., Stein P. K. Clinical application of heart rate variability after acute myocardial infarction. Front Physiol 2012; 3: 41.
3. Liu Y. H., Su J. Y., Wang L. J. et al. Impact of potentially lethal ventricular arrhythmias on long-term outcome in patients with chronic heart failure. Chin Med J (Engl) 2012; 125 (4):563–8.
4. Coons J. C., Plauger K. M., Seybert A. L. et al. Worsening heart failure in the setting of dronedarone initiation. Ann Pharmacother 2010; 44 (9):1496–500.
5. Swedberg K., Komajda M., Behm M. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744):875–85.
6. Tardif J. C. Heart rate as a treatable cardiovascular risk factor. Br Med Bull 2009; 90:71–84.
7. Tanindi A., Olgun H., Celik B. et al. Heart rate variability in patients hospitalized for decompensated diastolic heart failure at admission and after clinical stabilization. Future Cardiol 2012; 8 (3): 473–82.
8. Agarwal S. K., Simpson R. J. Jr., Rautaharju P. et al. Relation of ventricular premature complexes to heart failure (from the Atherosclerosis Risk In Communities (ARIC) Study). Am J Cardiol 2012; 109 (1):105–9.
9. Kapoor J. R., Heidenreich P. A. Role of heart rate as a marker and mediator of poor outcome for patients with heart failure. Curr Heart Fail Rep 2012; 9 (2):133–8.
10. Ulu N., Henning R. H., Goris M. et al. Effects of ivabradine and metoprolol on cardiac angiogenesis and endothelial dysfunction in rats with heart failure. J Cardiovasc Pharmacol 2009; 53 (1):9–17.
11. Hofmann F., Fabritz L., Stieber J. et al. Ventricular HCN channels decrease the repolarization reserve in the hypertrophic heart. Cardiovasc Res 2012;95 (3):317–26.
12. Koncz I., Szél T., Bitay M. et al. Electrophysiological effects of ivabradine in dog and human cardiac preparations: potential antiarrhythmic action. Eur J Pharmacol 2011; 668 (3):419–26.
13. Speranza L., Franceschelli S., Riccioni G. The biological effects of ivabradine in cardiovascular disease. Molecules 2012; 17 (5):4924–35.
14. López-Bescós.L, Filipova S., Martos R. on behalf of the studyinvestigators. Long-Term Safety and Efficacy of Ivabradine in Patients with Chronic Stable Angina. Cardiology 2007; 108:387–96.
15. Becher P. M., Lindner D., Miteva K. et al. Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and β-receptor blockade. Hypertension 2012; 59 (5):949–57.
Review
For citations:
Surovtseva M.V., Koziolova N.A., Chernyavina A.I. DYNAMICS OF HEART RATE VARIABILITY AND VENTRICULAR ECTOPIC ACTIVITY IN IVABRADINE-TREATED PATIENTS WITH CHRONIC HEART FAILURE. Russian Journal of Cardiology. 2012;(6):60-65. (In Russ.)